RMTG CEO says Nasdaq uplisting remains long-term goal, timing uncertain

Management flagged rising liabilities, interest expense and derivatives tied to funding growth and acquisitions, and said the strategy centers on scaling higher-margin recurring revenue.

Q1 2026 revenue rose 90% year over year, and Q2 revenue quadrupled, supported by education-led growth through ISSCA and related product pull-through.

The BKFC partnership was positioned as a marketing and clinical channel, and management expects additional public announcements, citing fighter Ben Rothwell's treatment.

ISSCA Ai was described as a physician tool built on 30 years of 60 million redacted records, aimed at deepening member relationships.

Regenerative Medical Technology Group management outlined a Nasdaq uplisting plan tied to meeting exchange financial and float thresholds, without timing guidance.

Management said the uplisting remains a long-term goal, but timing is uncertain.